208 related articles for article (PubMed ID: 10853979)
1. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis.
Arribas JR; Hernández-Albujar S; González-García JJ; Peña JM; Gonzalez A; Cañedo T; Madero R; Vazquez JJ; Powderly WG
AIDS; 2000 May; 14(8):979-85. PubMed ID: 10853979
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
3. Changes in oropharyngeal colonization and infection by Candida albicans in human immunodeficiency virus-infected patients.
Diz Dios P; Ocampo A; Otero I; Iglesias I; Martínez C
J Infect Dis; 2001 Jan; 183(2):355-356. PubMed ID: 11120936
[No Abstract] [Full Text] [Related]
4. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
Lucas GM; Chaisson RE; Moore RD
AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
[TBL] [Abstract][Full Text] [Related]
5. Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter.
Wu CJ; Lee HC; Yang YL; Chang CM; Chen HT; Lin CC; Lee NY; Chu WL; Hsieh LY; Wang YL; Lauderale TL; Tseng FC; Ko NY; Ko WC; Lo HJ
Clin Microbiol Infect; 2012 May; 18(5):485-90. PubMed ID: 21939471
[TBL] [Abstract][Full Text] [Related]
6. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
Deeks SG; Hecht FM; Swanson M; Elbeik T; Loftus R; Cohen PT; Grant RM
AIDS; 1999 Apr; 13(6):F35-43. PubMed ID: 10397555
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Bellman PC
AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
[TBL] [Abstract][Full Text] [Related]
8. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
[TBL] [Abstract][Full Text] [Related]
9. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
Lederman MM; Connick E; Landay A; Kuritzkes DR; Spritzler J; St Clair M; Kotzin BL; Fox L; Chiozzi MH; Leonard JM; Rousseau F; Wade M; Roe JD; Martinez A; Kessler H
J Infect Dis; 1998 Jul; 178(1):70-9. PubMed ID: 9652425
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
[TBL] [Abstract][Full Text] [Related]
12. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
Chêne G; Binquet C; Moreau JF; Neau D; Pellegrin I; Malvy D; Ceccaldi J; Lacoste D; Dabis F
AIDS; 1998 Dec; 12(17):2313-20. PubMed ID: 9863874
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
[TBL] [Abstract][Full Text] [Related]
14. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
Staszewski S; Miller V; Sabin C; Schlecht C; Gute P; Stamm S; Leder T; Berger A; Weidemann E; Hill A; Phillips A
AIDS; 1999 May; 13(8):951-6. PubMed ID: 10371176
[TBL] [Abstract][Full Text] [Related]
15. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients.
Revankar SG; Sanche SE; Dib OP; Caceres M; Patterson TF
AIDS; 1998 Dec; 12(18):2511-3. PubMed ID: 9875598
[No Abstract] [Full Text] [Related]
16. Predisposing factors for oropharyngeal colonization of yeasts in human immunodeficiency virus-infected patients: a prospective cross-sectional study.
Lin JN; Lin CC; Lai CH; Yang YL; Chen HT; Weng HC; Hsieh LY; Kuo YC; Lauderdale TL; Tseng FC; Lin HH; Lo HJ
J Microbiol Immunol Infect; 2013 Apr; 46(2):129-35. PubMed ID: 22921200
[TBL] [Abstract][Full Text] [Related]
17. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment.
Chougnet C; Fowke KR; Mueller BU; Smith S; Zuckerman J; Jankelevitch S; Steinberg SM; Luban N; Pizzo PA; Shearer GM
AIDS; 1998 Dec; 12(18):2397-406. PubMed ID: 9875577
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
[TBL] [Abstract][Full Text] [Related]
20. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
